Pfizer Forms Immunological Research Pact
Pfizer's Centers for Therapeutic Innovation (CTI) and the Jeffrey Modell Foundation (JMF), a global non-profit organization for immunological diseases, have formed a collaboration for immunological disease.
CTI and JMF will identify and co-fund translational research projects with academic medical centers within the CTI network to identify and validate a potential drug candidate for an immunological disease that can be moved into further clinical testing. Pfizer's CTI works alongside academic teams using its local centers in biomedical research hubs to bridge the gap between early scientific discovery and its translation into potential new medicines. CTI now has 25 academic institutions and six foundations in its network.
JMF has created the Jeffrey Modell Centers Network, which includes 125 diagnostic and research centers, 600 physicians, and 248 academic institutions.